Dbv technologies to present new data at acaai 2023

Montrouge, france, november 2, 2023 dbv technologies to present new data at acaai 2023 new data to include late-breaking abstract detailing interim 12-month results from the ongoing phase 3 open-label extension to the epitope trial (epopex) of viaskin™ peanut in peanut-allergic toddlers. dbv technologies (euronext: dbv – isin: fr0010417345 – nasdaq stock market: dbvt), a clinical-stage biopharmaceutical company, today announced that new data on the use of viaskin™ peanut (dbv712) 250 Μg in peanut-allergic toddlers will be presented at the american college of allergy, asthma & immunology (acaai) annual scientific meeting, which is being held thursday, november 9 – monday, november 13, 2023, in anaheim, ca.
DBVT Ratings Summary
DBVT Quant Ranking